Plasminogen activator inhibitor-1 and thrombotic cerebrovascular diseases - Wikidata - wikimedia - TriplyDB

Plasminogen activator inhibitor-1 and thrombotic cerebrovascular diseases

Plasminogen activator inhibitor-1 and thrombotic cerebrovascular diseases

http://www.wikidata.org/entity/Q37017506

about

Dysfunction of annexin A2 contributes to hyperglycaemia-induced loss of human endothelial cell surface fibrinolytic activity Profibrinolytic effect of the epigenetic modifier valproic acid in man.TGF-β superfamily gene expression and induction of the Runx1 transcription factor in adult neurogenic regions after brain injury.SIRT1-mediated epigenetic downregulation of plasminogen activator inhibitor-1 prevents vascular endothelial replicative senescence Defining a conformational consensus motif in cotransin-sensitive signal sequences: a proteomic and site-directed mutagenesis study.Decreased Insulin Sensitivity and Impaired Fibrinolytic Activity in Type 2 Diabetes Patients and Nondiabetics with Ischemic Stroke.Plasma tPA-Activity and Progression of Cerebral White Matter Hyperintensities in Lacunar Stroke Patients.Early insulin glycemic control combined with tPA thrombolysis reduces acute brain tissue damages in a focal embolic stroke model of diabetic rats Hyperglycaemia-induced reciprocal changes in miR-30c and PAI-1 expression in platelets.Association between plasminogen activator inhibitor-1 gene polymorphisms and recurrent pregnancy loss: a systematic review and meta-analysis.What causes intracerebral bleeding after thrombolysis for acute ischaemic stroke? Recent insights into mechanisms and potential biomarkers.Species-Specific Regulation of t-PA and PAI-1 Gene Expression in Human and Rat Astrocytes Plasminogen activator inhibitor links obesity and thrombotic cerebrovascular diseases: The roles of PAI-1 and obesity on stroke.Vehicle-dependent Effects of Sphingosine 1-phosphate on Plasminogen Activator Inhibitor-1 Expression.Comparative effects of pulsatile and nonpulsatile flow on plasma fibrinolytic balance in pediatric patients undergoing cardiopulmonary bypass.Retrospective evaluation of the incidence and prognostic significance of spontaneous echocardiographic contrast in relation to cardiac disease and congestive heart failure in cats: 725 cases (2006-2011).Adipose Tissue-Derived Plasminogen Activator Inhibitor-1 Function and Regulation.Cerebral infarction and femoral venous thrombosis detected in a patient with diabetic ketoacidosis and heterozygous factor V Leiden G1691A and PAI-1 4G/5G mutations.

P2860

Q33789283-E44AF992-2083-40B6-BFF3-50A9C0F542A0 Q34306821-58E5E306-02F9-4972-8540-E778FEA3C1F0 Q34650960-0C689377-7A81-4DA7-99A2-076734BD7E58 Q35093088-0BFAB590-6120-4A02-AA42-5B468AF56BCB Q35217384-C140EEAC-477D-4952-BA2B-DCEECF1BBC07 Q35673977-5AF5B56A-B826-4B74-B1B5-7E6A40700E2B Q35945812-65CAC1DA-B5CE-4E29-98D5-2A5812E54E78 Q36692675-AC5BEAC8-19F0-4CBA-9B69-AF76235C8EBC Q37397301-8FAD8CAC-3151-4CF0-BBD2-0BA80511E9BF Q38253818-02053098-7984-45BD-8F1C-D3BC80FCA64E Q38392999-9188EE09-C01C-4EEA-9034-02790B5DFD10 Q39187550-DEE3031F-C939-4A77-BDDB-C580526DBC1D Q39220804-434B84B9-F165-4079-B720-C147995F0708 Q40287159-85D50A27-0F03-4912-8F89-B29ED353EDA4 Q45266950-71C28B86-7880-4C91-AD02-770E6F0AD7FA Q46685689-EC77F5B1-7108-4684-A3A6-41E0DE1FC29F Q51361802-5852FD97-7BFF-43D8-89A7-A581204EF2DD Q51631834-5FC7EF31-181B-46D0-82C7-BAC1DA157A43

P2860

Plasminogen activator inhibitor-1 and thrombotic cerebrovascular diseases

http://www.wikidata.org/entity/Q37017506

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 09 August 2012

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Plasminogen activator inhibitor-1 and thrombotic cerebrovascular diseases

@en

Plasminogen activator inhibitor-1 and thrombotic cerebrovascular diseases.

@nl

type

label

Plasminogen activator inhibitor-1 and thrombotic cerebrovascular diseases

@en

Plasminogen activator inhibitor-1 and thrombotic cerebrovascular diseases.

@nl

prefLabel

Plasminogen activator inhibitor-1 and thrombotic cerebrovascular diseases

@en

Plasminogen activator inhibitor-1 and thrombotic cerebrovascular diseases.

@nl

P1433

Q37017506-347657B7-EED9-499D-B13A-C0F846C59715

P1476

Q37017506-28F4AEE3-EDF1-4A5A-9575-B507BDFD7589

P2093

Q37017506-5941C4DA-0370-47B4-AAC9-98CA8DED57D3

Q37017506-7106DA6B-DFA9-4847-8DCA-5A9E5688AA68

Q37017506-AFE7FF76-2B20-4378-BD7F-074F99751545

Q37017506-E4CD99CC-1206-4029-9A28-0B5C2923E0CB

P2860

Q37017506-099FD73A-BB86-414B-9E30-EAD11132DBD1

Q37017506-0CB66CF5-9DBF-4C3B-8587-B615CD49C1F9

Q37017506-1A801350-4497-47AC-9DAE-9FD4AFD82113

Q37017506-1CC81260-A945-4C0F-B7AD-3AC609CA082D

Q37017506-21BA2963-0800-4245-844A-2B9CAEED3B7F

Q37017506-223B7EB1-D91F-45CB-8229-8C773182300A

Q37017506-2410D920-AF85-49BB-BD9C-2577A170740D

Q37017506-277CC11C-9784-43C0-8310-9E95C786E0DD

Q37017506-2C941570-70DA-480D-90A4-2E290C0F44EA

Q37017506-2F4569E9-4CD6-4732-817A-75AA65E4C76B

P304

Q37017506-87CAF404-2679-407B-8C35-ECF2C9D31022

P31

Q37017506-FD75F3D0-5C95-41CE-B497-9A2322CF8207

P356

Q37017506-32B20ED2-0515-4419-A3A4-0E8B46DF26F0

P407

Q37017506-198BEB9B-26E8-450D-99DD-606B0F8B0FF6

P433

Q37017506-B4DDEB41-B9CC-4F3A-93B3-8B104BB5AC6A

P478

Q37017506-67AE343F-03C6-4422-BEC1-A7810541A881

P577

Q37017506-76281DF4-3183-459A-8DAE-226D8A7613FF

P698

Q37017506-F38FAF8F-69DE-4639-86F1-C51B65E45E6C

P932

Q37017506-F61B08D7-9202-4E72-8139-4C098ED6CFAB

P356

STROKEAHA.111.622217

P1433

P1476

Plasminogen activator inhibitor-1 and thrombotic cerebrovascular diseases

@en

P2093

Anna Tjärnlund-Wolf

http://www.w3.org/2001/XMLSchema#string

Eng H Lo

http://www.w3.org/2001/XMLSchema#string

Helen Brogren

http://www.w3.org/2001/XMLSchema#string

Xiaoying Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Antiplatelet agents and anticoagulants for hypertension

Causal relationship of susceptibility genes to ischemic stroke: comparison to ischemic heart disease and biochemical determinants

Platelets retain high levels of active plasminogen activator inhibitor 1

Blood pressure, stroke, and coronary heart disease

Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene.

Can inactivators of plasminogen activator inhibitor alleviate the burden of obesity and diabetes? (Review).

Attenuation of neointimal vascular smooth muscle cellularity in atheroma by plasminogen activator inhibitor type 1 (PAI-1).

Effect of atorvastatin on haemostasis, fibrinolysis and inflammation in normocholesterolaemic patients with coronary artery disease: a post hoc analysis of data from a prospective, randomized, double-blind study.

Plasminogen activator inhibitor-1, adipose tissue and insulin resistance.

A novel inhibitor of plasminogen activator inhibitor-1 provides antithrombotic benefits devoid of bleeding effect in nonhuman primates.

P304

2833-2839

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/STROKEAHA.111.622217

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

43

http://www.w3.org/2001/XMLSchema#string

P577

2012-08-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22879095

http://www.w3.org/2001/XMLSchema#string

P932

3712849

http://www.w3.org/2001/XMLSchema#string